Major amendments containing new clinical trial data or analyses are driving the high usage of three-month extensions to PDUFA goal dates over the past year, an analysis of the Pink Sheet’s US FDA Performance Tracker shows.
Furthermore, those major amendments are followed,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?